Research Article
Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer
Table 1
Patient and treatment characteristics: original and follow-up cohorts.
| | Characteristic | Original cohort (n = 34) | Follow-up cohort (n = 25) | value |
| | Age at diagnosis (yr), mean ± std | 49.6 ± 12.5 | 49.9 ± 11.5 | 0.92 | | Body mass index (kg/m2), mean ± std | 27.0 ± 5.2 | 26.7 ± 5.0 | 0.82 | | Smoker | 6 (17.6) | 5 (20.0) | 0.55 | | Stage | | I | 4 (11.8) | 4 (16.0) | 0.2 | | II | 21 (61.8) | 14 (56.0) | 0.24 | | III | 9 (26.5) | 7 (28.0) | 0.73 | | Adjuvant endocrine therapy | 24 (70.6) | 19 (76.0) | 0.24 | | Adjuvant trastuzumab | 7 (20.6) | 5 (20.0) | 0.89 | | Triple negative breast cancer | 8 (23.6) | 5 (20.0) | 0.41 | | Radiotherapy | | Tangential lymph nodes | 32 (94.1) | 23 (92.0) | 0.38 | | Tangential + regional lymph node fields | 15 (44.1) | 12 (48.0) | 0.44 | | DDC-related DLCO injury | 20 (58.8) | 16 (64.0) | 0.31 | | Breast cancer recurrence | 11 (32.4) | 6 (24.0) | 0.08 | | Breast cancer-related death | 7 (20.6) | 4 (16.0) | 0.27 | | Values are n (%) unless otherwise stated. | | Abbreviations: DDC, dose-dense chemotherapy; DLCO, carbon monoxide diffusing capacity |
|
|
